Cyclophosphamide for myasthenia gravis: a comeback?

JNNP podcast by BMJ Group

Apr 17, 202537:58Science & Medicine

Patients with refractory or high-risk myasthenia gravis (MG) respond poorly to conventional immunosuppressive therapy, requiring rescue therapies and often experiencing treatment toxicity. The study discussed in this pod...

Related Episodes

Continue listening to more episodes from JNNP podcast.

Neurocognitive and psychiatric effects after mild COVID-19: meta-analytic evidence

Sep 4, 2025 - 33:06

The meta‑analysis discussed in this podcast reveals that adults recovering from COVID‑19 without major me...

Vestibular neurology for the generalist

Jun 16, 2025 - 46:18

This episode guides the general neurologist through diagnosing and treating dizziness, vertigo, and balan...

Management methods for acute ischaemic stroke

Feb 13, 2025 - 26:38

The effectiveness of endovascular treatment (EVT) in cases of acute ischaemic stroke caused by distal med...

Distinguishing autoimmune nodopathies from CIDP, with Dr. Ruth Huizinga and Dr. Maarten Titulaer

Jul 15, 2024 - 38:57

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) can be difficult to distinguish from aut...

Nutritional peripheral neuropathies, with Dr. Alexander Rossor

Apr 17, 2024 - 39:42

The cause of a nutritional neuropathy may not always be obvious when first examining a patient. Restricti...

Distinguishing primary from functional tics

Feb 19, 2024 - 40:02

How often do movement disorder specialists agree when classifying tics? A recent study published in JNNP...

Nitrous Oxide Abuse

Sep 22, 2023 - 27:45

With the UK government announcing plans to make recreational use of nitrous oxide illegal, JNNP podcast h...

Brain Fog Demystified

Aug 8, 2023 - 30:15

Social media platforms and clinical patient encounters are abundant in references to brain fog, but how m...